Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer
Hossein Borghaei, Katherine Alpaugh, Gunnar Hedlund, Göran Forsberg, Corey Langer, Andre Rogatko, Robert Hawkins, Svein Dueland, Ulrik Lassen, Roger B Cohen
Dive into the research topics of 'Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer'. Together they form a unique fingerprint.